Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes

被引：61

作者：

Jacqueminet, Sophie ^{[2
]}

Lebray, Pascal ^{[1
]}

Morra, Rachel ^{[5
]}

Munteanu, Mona ^{[5
]}

Devers, Laure ^{[4
]}

Messous, Djamila ^{[3
]}

Bernard, Maguy ^{[3
]}

Hartemann-Heurtier, Agnes ^{[2
]}

Imbert-Bismut, Francoise ^{[3
]}

Ratziu, Vlad ^{[1
]}

Grimaldi, Andre ^{[2
]}

Poynard, Thierry ^{[1
]}

机构：

[1] Grp Hosp Pitie Salpetriere, AP HP, Serv Hepatol, F-75651 Paris 13, France

[2] Grp Hosp Pitie Salpetriere, AP HP, Serv Diabetol, F-75651 Paris, France

[3] Grp Hosp Pitie Salpetriere, AP HP, Serv Biochim, F-75651 Paris 13, France

[4] Grp Hosp Pitie Salpetriere, AP HP, Unite Transfus, F-75651 Paris 13, France

[5] Serv Biopredict, Paris, France

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2008年 / 6卷 / 07期

关键词：

D O I：

10.1016/j.cgh.2008.03.005

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background & Aims: Patients with diabetes are at risk for nonalcoholic fatty liver disease leading to advanced fibrosis, cirrhosis, and liver cancer. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) in patients with diabetes. Methods: We prospectively studied 1131 consecutive patients without a history of liver disease seen for diabetes. The biomarker data were obtained, and patients with presumed advanced fibrosis were reinvestigated by a hepatologist using elastography and, if necessary, ultrasonography, endoscopy, or liver biopsy. Results: The biomarker predicted advanced fibrosis in 63 of 1131 (5.6%) patients. A total of 45 patients was reinvestigated, and advanced fibrosis was confirmed in 32 patients, a 2.8% (32/1131) prevalence of confirmed advanced fibrosis, 5 cases of cirrhosis, and 4 cases of hepatocellular carcinoma. In the population with type 2 diabetes who were 45 years or older, the prevalence of confirmed advanced fibrosis was 4.3% (30/696), and hepatocellular carcinoma was 5.7 of 1000 (4/696). Conclusions: The fibrosis biomarker might be used for the detection of advanced fibrosis in patients with type 2 diabetes.

引用

页码：828 / 831

页数：4

共 17 条

[1]

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].

Angulo, Paul ;

Hui, Jason M. ;

Marchesini, Giulio ;

Bugianesi, Ellisabetta ;

George, Jacob ;

Farrell, Geoffrey C. ;

Enders, Felicity ;

Saksena, Sushma ;

Burt, Alastair D. ;

Bida, John P. ;

Lindor, Keith ;

Sanderson, Schuyler O. ;

Lenzi, Marco ;

Adams, Leon A. ;

Kench, James ;

Therneau, Terry M. ;

Day, Christopher P. .

HEPATOLOGY, 2007, 45 (04) :846-854

[2]

Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines? [J].

Castera, Laurent ;

Denis, Jacques ;

Babany, Gerard ;

Roudot-Thoraval, Francoise .

JOURNAL OF HEPATOLOGY, 2007, 46 (03) :528-+

[3]

Long-term follow-up of patients with NAFLD and elevated liver enzymes [J].

Ekstedt, Mattias ;

Franzen, Lennart E. ;

Mathiesen, Ulrik L. ;

Thorelius, Lars ;

Holmqvist, Marika ;

Bodemar, Goran ;

Kechagias, Stergios .

HEPATOLOGY, 2006, 44 (04) :865-873

[4]

The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence [J].

El-Serag, HB ;

Hampel, H ;

Javadi, F .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (03) :369-380

[5]

Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations [J].

Foucher, Juliette ;

Castera, Laurent ;

Bernard, Pierre-Henri ;

Adhoute, Xavier ;

Laharie, David ;

Bertet, Julien ;

Couzigou, Patrice ;

de Ledinghen, Victor .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (04) :411-412

[6]

Transient elastography:: a valid alternative to biopsy in patients with chronic liver disease [J].

Gomez-Dominguez, E. ;

Mendoza, J. ;

Rubio, S. ;

Moreno-Monteagudo, J. A. ;

Garcia-Buey, L. ;

Moreno-Otero, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (03) :513-518

[7]

*HAS FRANC, HAS REC MAN CHRON HE

[8]

Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors [J].

Imbert-Bismut, F ;

Messous, D ;

Thibaut, V ;

Myers, RB ;

Piton, A ;

Thabut, D ;

Devers, L ;

Hainque, B ;

Mercadier, A ;

Poynard, T .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (03) :323-333

[9]

FibroMAX ™:: towards a new universal biomarker of liver disease? [J].

Morra, Rachel ;

Munteanu, Mona ;

Imbert-Bismut, Francoise ;

Messous, Djamila ;

Ratziu, Wad ;

Poynard, Thierry .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (05) :481-490

[10]

Munteanu M, 2007, HEPATOLOGY, V46, p748A

← 1 2 →